Skip to main content

Table 1 Odd ratios (with confidence intervals) and heterogeneity for each of the cancer risks analysed

From: Ovulation induction drug and ovarian cancer: an updated systematic review and meta-analysis

Outcome

OR

95% CI

I2

Degree of heterogeneity

The risk of IOC between OI and CT group (based on case-control study)

1.09

0.88-1.35

54.9%

Moderate

The risk of BOT between OI and CT group (based on case-control study)

1.90

0.89-4.09

73.4%

Moderate

The risk of IOC between OI and CT group (based on cohort study)

1.11

0.91-1.35

21.8%

Low

The risk of BOT between OI and CT group (based on cohort study)

1.34

0.97-1.83

50.5%

Moderate

The risk of IOC between OI and CT group (in multiparous women)

0.83

0.65-1.05

21.3%

Low

The risk of BOT between OI and CT group (in nulliparous women)

1.17

0.55-2.48

73.5%

Moderate

The risk of IOC between OI and CT group (in nulliparous women)

1.55

0.94-2.57

69.5%

Moderate

The risk of BOT between OI and CT group (in nulliparous women)

1.49

1.03-2.15

0%

Low

The risk of IOC between the nulliparous and multiparous women (with ovulation induction treatment)

3.35

2.10-5.34

52.2%

Moderate

The risk of BOT between the nulliparous and multiparous women (with ovulation induction treatment)

2.58

1.76-3.79

0%

Low

The risk of IOC between OI and CT group (less than 3 ovulation induction cycles)

1.05

0.72-1.52

42.9%

Low

The risk of IOC between OI and CT group (more than 3 ovulation induction cycles)

0.98

0.79-1.22

0%

Low

The risk of IOC between OI and CT group (less than 6 ovulation induction cycles)

0.85

0.64-1.12

0%

Low

The risk of IOC between OI and CT group (more than 6 ovulation induction cycles)

0.88

0.59-1.31

0%

Low

The risk of IOC between OI and CT group (less than 12 ovulation induction cycles)

0.87

0.69-1.10

0%

Low

The risk of IOC between OI and CT group (more than 12 ovulation induction cycles)

0.78

0.49-1.22

0%

Low

The risk of IOC between CC and CT group

1.01

0.88-1.17

0%

Low

The risk of BOT between CC and CT group

1.32

0.79-2.21

72.6%

Moderate

The risk of IOC between GDT and CT group

1.08

0.80-1.44

0%

Low

The risk of BOT between GDT and CT group

1.73

0.88-1.93

54.1%

Moderate

The risk of IOC between HCG and CT group

1.10

0.71-1.71

34.7%,

Low

The risk of BOT between HCG and CT group

1.28

0.71-2.31

56%

Moderate

The risk of IOC between HMG and CT group

1.07

0.44-2.57

71.6%

Moderate

The risk of BOT between HMG and CT group

5.31

0.73-38.72

83.3%

High

The risk of IOC between GnRH-a and CT group

0.49

0.07-3.66

71.9%

Moderate

  1. CC Clomiphene citrate, GDT Gonadotrophin, GnRH-a Gonadotropin-releasing hormone analogues, HCG human menopausal gonadotropin, HMG human chorionic gonadotropin, IOC invasive ovarian cancer, BOT borderline ovarian tumor, OI ovulation induction group, CT control group, OR odds ratio, 95%CI 95% confidence interval